D
Capricor Therapeutics, Inc. CAPR
$6.89 -$0.41-5.62% NASDAQ
Recommendation
Prev Close
$6.89
Volume
15,474
Avg Vol (90D)
1,373,635
Market Cap
$314.71M
Dividend & Yield
--
52-Week Range
$3.52 - $23.40
P/E (TTM)
--
EPS (TTM)
-$1.20
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Capricor Therapeutics (CAPR) Projected to Post Quarterly Earnings on Monday
5/7/2025 - MarketBeat
Freestone Grove Partners LP Buys New Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR)
5/7/2025 - MarketBeat
Capricor Therapeutics (CAPR, $7.3) Moving Average Convergence Divergence (MACD) Histogram turned negative on May 6, 2025
5/7/2025 - Tickeron - Technical Analysis
Capricor Therapeutics (CAPR, $7.3) RSI Indicator left the oversold zone on May 06, 2025
5/7/2025 - Tickeron - Technical Analysis
Noteworthy Tuesday Option Activity: CAPR, LMND, SYRE
5/6/2025 - Stock Options Channel
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate ...
5/6/2025 - GuruFocus
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate ...
5/6/2025 - GuruFocus
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13
5/6/2025 - Globe Newswire
Capricor Therapeutics (CAPR, $10.3) entered Downtrend as Momentum indicator drops below 0 level on May 05, 2025
5/6/2025 - Tickeron - Technical Analysis
capricor shares red fda announces deramiocel adcomm first under commissioner makary
5/6/2025 - FierceBiotech.com - Biotech
Capricor Therapeutics (CAPR) Faces FDA Advisory Meeting for Duchenne Treatment CAPR Stock News
5/5/2025 - GuruFocus
Capricor FDA panel meeting 'not unexpected,' says JonesResearch
5/5/2025 - TipRanks Financial Blog
Capricor Therapeutics (CAPR) Faces FDA Advisory Meeting, Shares Drop
5/5/2025 - GuruFocus
Capricor Therapeutics Stock Tumbles After FDA Confirms Intent To Hold Advisory Committee Meet For Deramiocel Approval: But Retail's Optimistic
5/5/2025 - Stocktwits News Feed
Capricor Therapeutics (CAPR) Anticipates Positive FDA Review Despite Stock Dip CAPR Stock News
5/5/2025 - GuruFocus
CAPR: Capricor Therapeutics Advances FDA Review for Deramiocel CAPR Stock News
5/5/2025 - GuruFocus
Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel ...
5/5/2025 - GuruFocus
Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
5/5/2025 - Globe Newswire
59,303 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Purchased by Marshall Wace LLP
5/3/2025 - MarketBeat
Capricor Therapeutics Inc (NASDAQ:CAPR) Receives Average Recommendation of "Buy" from Brokerages
5/2/2025 - MarketBeat
Capricor Therapeutics Inc (NASDAQ:CAPR) Receives Average Rating of "Buy" from Analysts
4/30/2025 - Ticker Report
Capricor Therapeutics (CAPR, $13.15) RSI Indicator left the overbought zone on April 23, 2025
4/24/2025 - Tickeron - Technical Analysis
Capricor Therapeutics (NASDAQ:CAPR) Trading 4.8% Higher - Here's Why
4/23/2025 - MarketBeat
Capricor Therapeutics (CAPR, $13.89) RSI Indicator left the overbought zone on April 22, 2025
4/23/2025 - Tickeron - Stocks
Bullish Two Hundred Day Moving Average Cross - CAPR
4/21/2025 - Market News Video
Income Statement
Total Revenue (TTM)
$22.27M
EBITDA (TTM)
-$41.14M
EBIT (TTM)
-$42.56M
Net Income (TTM)
-$40.47M
Balance Sheet
Total Assets (Q)
$170.48M
Total Debt (Q)
$1.45M
Total Liabilities (Q)
$25.02M
Book Value Per Share (Q)
$3.19
Cash Flow
Cash from Operations (TTM)
-$40.00M
Cash from Investing (TTM)
-$116.18M
Cash from Financing (TTM)
$152.77M
Net Change in Cash (TTM)
-$3.41M
Filings
Filing Date
Wednesday, March 26, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
1.27
7-Day Total Return
-45.14%
30-Day Total Return
-47.72%
60-Day Total Return
-48.89%
90-Day Total Return
-51.07%
Year to Date Total Return
-53.94%
1-Year Total Return
28.31%
2-Year Total Return
76.67%
3-Year Total Return
120.83%
5-Year Total Return
-2.27%
52-week Low
Aug 07, 2024 - $3.52
52-week High
Oct 15, 2024 - $23.40
Valuation
Market Cap
$314.71M - Small Cap
Enterprise Value
$164.65M
Price/Sales (TTM)
13.77
Price/Book (Q)
2.16
Dividends and Shares
Shares Outstanding
44.51M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.capricor.com
Phone Number
858 727 1755
Address
10865 Road to the Cure
San Diego, CA 92121
Country
United States
Year Founded
2005
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy... more
NASDAQ 05/07/2025 4:00PM Eastern Quotes delayed